TP53 and pancreatic neoplasm: We, and others, have recently described the inducible-Kras*p53+/− (iKras*p53+/−) mouse model of pancreatic cancer, that allows tissue-specific, inducible and reversible expression of mutant Kras in combination with a loss of function allele of the tumor suppressor p53 [8], [9].